Skip to main content

Table 1 Characteristics of older adults newly prescribed and not prescribed ezetimibe within six months of a hospital discharge for an AMI

From: Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study

  No Ezetimibe Prescription N = 69, 895 New Ezetimibe Prescription N = 1230 Standardized Difference
Age N % N %  
Mean (SD) 78.42 7.72 74.84 6.43 50%
Median (IQR) 78 (72–84) 74 (69–79)  
Female 31, 995 45.8% 559 45.4% 1%
Rural location 11, 497 16.4% 224 18.2% 5%
Income quintile
 1 (lowest) 15, 454 22.1% 243 19.8% 6%
 2 14, 762 21.1% 253 20.6% 1%
 3 14, 028 20.1% 257 20.9% 2%
 4 13, 162 18.8% 256 20.8% 5%
 5 (highest) 12, 489 17.9% 221 18.0% 0%
Long-term care 3587 5.1% < 6 < 0.5%
Year of hospital discharge
 2005 8390 12.0% 131 10.7% 4%
 2006 7678 11.0% 174 14.1% 10%
 2007 7974 11.4% 187 15.2% 11%
 2008 7786 11.1% 121 9.8% 4%
 2009 7537 10.8% 114 9.3% 5%
 2010 7585 10.9% 127 10.3% 2%
 2011 7530 10.8% 148 12.0% 4%
 2012 7572 10.8% 117 9.5% 4%
 2013 7843 11.2% 111 9.0% 7%
Rostered to a family physician 55, 396 79.3% 1015 82.5% 8%
Comorbiditiesa
Coronary artery disease 27, 838 39.8% 509 41.4% 3%
Stroke/Transient ischemic attack 3012 4.3% 40 3.3% 5%
Diabetes 64, 973 93.0% 1102 89.6% 12%
Peripheral vascular disease 2199 3.1% 36 2.9% 1%
Chronic kidney disease 8809 12.6% 123 10.0% 8%
Dialysis 1080 1.5% 10 0.8% 7%
Hypertension 64, 745 92.6% 1094 88.9% 13%
Liver disease 1905 2.7% 32 2.6% 1%
Congestive heart failure 14, 634 20.9% 146 11.9% 24%
Coronary revascularization 2555 3.7% 71 5.8% 10%
Charlson comorbidity index
 0 (no hospitalizations) 46, 300 66.2% 921 74.9% 19%
 1 7498 10.7% 114 9.3% 5%
 2 6248 8.9% 95 7.7% 4%
 3 or higher 9849 14.1% 100 8.1% 19%
Healthcare Utilizationb
Visit to a family physician 66, 325 94.9% 1165 94.7% 1%
Visit to cardiologist 32, 321 46.2% 559 45.4% 2%
Visit to endocrinologist 5025 7.2% 106 8.6% 5%
Visit to internist 24, 020 34.4% 393 32.0% 5%
Evidence of at least 1 cholesterol test 35, 060 50.2% 797 64.8% 30%
Baseline medicationsc
Any statin 30, 329 43.4% 556 45.2% 4%
Statin intensityd
 Low 2335 3.3% 29 2.4% 5%
 Moderate 20, 626 29.5% 314 25.5% 9%
 High 6857 9.8% 205 16.7% 20%
 Other 511 0.7% 8 0.7% 0%
Fibrates 1430 2.0% 56 4.6% 15%
Thienopyridines 1576 2.3% 21 1.7% 4%
Beta-blocker 24, 614 35.2% 438 35.6% 1%
Angiotensin converting enzyme inhibitor 25, 701 36.8% 415 33.7% 6%
Angiotensin receptor blocker 14, 131 20.2% 303 24.6% 11%
  1. Unless indicated, data presented as number and percentage
  2. Standardized differences > 10% are considered meaningful
  3. Cell sizes < 6 are not presented for patient privacy
  4. aComorbidities were ascertained in the 5 years prior to their hospitalization for an AMI
  5. bHealthcare utilization was ascertained in the 1 year prior to their hospitalization for an AMI
  6. cBaseline medications were examined in the 120 days prior to their AMI hospitalization
  7. dIntensity of statin therapy was categorized based upon guideline recommendations from the American College of Cardiology